1. Home
  2. CNK vs IMVT Comparison

CNK vs IMVT Comparison

Compare CNK & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cinemark Holdings Inc Cinemark Holdings Inc.

CNK

Cinemark Holdings Inc Cinemark Holdings Inc.

HOLD

Current Price

$23.12

Market Cap

2.7B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$25.14

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNK
IMVT
Founded
1984
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
5.3B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
CNK
IMVT
Price
$23.12
$25.14
Analyst Decision
Strong Buy
Buy
Analyst Count
10
10
Target Price
$34.70
$27.75
AVG Volume (30 Days)
4.6M
2.0M
Earning Date
02-18-2026
02-05-2026
Dividend Yield
1.38%
N/A
EPS Growth
N/A
N/A
EPS
1.11
N/A
Revenue
$3,153,000,000.00
N/A
Revenue This Year
$6.18
N/A
Revenue Next Year
$7.60
N/A
P/E Ratio
$20.76
N/A
Revenue Growth
9.70
N/A
52 Week Low
$21.60
$12.72
52 Week High
$34.01
$27.69

Technical Indicators

Market Signals
Indicator
CNK
IMVT
Relative Strength Index (RSI) 40.41 51.46
Support Level $22.44 $26.35
Resistance Level $23.21 $27.64
Average True Range (ATR) 0.81 1.41
MACD 0.09 -0.15
Stochastic Oscillator 39.34 52.05

Price Performance

Historical Comparison
CNK
IMVT

About CNK Cinemark Holdings Inc Cinemark Holdings Inc.

Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: